MOLECULAR AND CELL BIOLOGY CORE (MCB CORE)

载脂蛋白E（apoE）受体，低密度脂蛋白受体（LDLR）家族的成员， 包含共同的结构模块和共享的序列同源物。该领域的主要挑战之一是 apoE受体生物学的研究重点是开发受体特异性试剂，包括抗体和细胞系。在 过去，Bu博士的实验室已经开发了apoE/apoE受体的独特和特异性试剂， LaDu、Alzhek、Estus和Weeber，其中许多试剂已在初步试验期间得到验证。 这个项目的规划阶段。分子细胞生物学（MCB）核心的总体目标是促进 通过开发、组织和分发apoE/apoE受体试剂， 进行与我们所提议的研究相关的基本分析。MCB核心的五个具体目标是： 1)开发和储存apoE和apoE受体特异性抗体、cDNA、细胞系和siRNA; 2） 将这些试剂和方案分发给各个实验室，因为它们变得可用或需要; 3）执行 apoE、apoE受体、淀粉样蛋白p肽（Ap）和Ap斑块的标准化测定; 4）制备两种新的 转基因小鼠系，并协助个别项目，以研究在这些体内apoE受体的作用， 新的和现有的转基因和基因敲除小鼠; 5）与个别项目合作研究apoE 阿尔茨海默病患者大脑中的受体蛋白水解。MCB核心的具体计划包括指定的 技术人员在卜博士的指导下开发、组织和监督该核心设施， 一个易于访问的数据库，记录了可用的试剂和使用它们的协议。布医生和 技术人员还将为最终用户提供技术问题和麻烦的咨询 拍摄这些核心服务将允许所有单个项目访问我们独特的 apoE/apoE受体试剂和几种标准化测定。预计这五个国家中的每一个都将 项目将使用MCB核心的试剂和服务。

Apolipoprotein E (apoE) receptors, members of the low-density lipoprotein receptor (LDLR) family, contain common structure modules and share sequence homologue. One of the major challenges in the field of apoE receptor biology is to develop receptor-specific reagents including antibodies and cell lines. In the past, unique and specific reagents for apoE/apoE receptors have been developed by the labs of Drs. Bu, LaDu, Rebeck, Estus, and Weeber, and many of these reagents have been validated during the preliminary stage of this program project. The overall goal of the Molecular Cell Biology (MCB) Core is to facilitate studies in this program project by developing, organizing, and distributing apoE/apoE receptor reagents, and to carry out essential assays pertinent to our proposed studies. The five specific aims of the MCB Core are: 1) to develop and store apoE and apoE receptor-specific antibodies, cDNAs, cell lines, and siRNAs; 2) to distribute these reagents and protocols to individual labs as they become available or needed; 3) to perform standardized assays for apoE, apoE receptors, amyloid p-peptide (Ap), and Ap plaques; 4) to make two new transgenic mouse lines and to assist individual projects to study the in vivo role of apoE receptors in these new and existing transgenic and knockout mice; and 5) to collaborate with individual projects to study apoE receptor proteolysis in Alzheimer's disease brains. The specific plans for the MCB Core include a designated technical personnel under the guidance of Dr. Bu to develop, organize, and supervise this Core facility and an easily accessible database documenting the available reagents and the protocols using them. Dr. Bu and the technical personnel will also provide consultations for the end users for technical issues and trouble shooting. These Core services will allow all individual projects to have access to our unique collection of apoE/apoE receptor reagents and to several standardized assays. It is anticipated that each of the five projects will utilize reagents and services from the MCB Core.